EML4-ALK mutation in Austrian patients with NSCLC: A multicenter study.

e19093 Background: EML4 (echinoderm microtubule-associated protein-like 4) - ALK (anaplastic lymphoma kinase) fusion-type tyrosine kinase, an oncoprotein found in a subgroup of non-small-cell lung cancer (NSCLC) predicts the response to ALK inhibitors. In general, AML4-ALK mutation is found in 2 to 7% of Caucasian patients with NSCLC and occurs more often in never and former smokers, adenocarcinomas, and younger, male patients. However, the frequency of EML4-ALK mutation in Austrian patients with NSCLC is unknown. The aim of the study was to evaluate the prevalence of EML4-ALK mutation in Austrian patients with NSCLC. Methods: From September 2011 to October 2012 tumour tissue from bronchoscopy, CT- and ultrasound guided biopsies and surgical specimen with histological type of adenocarcinoma and NSCLC NOS (Not Otherwise Specified) excluding squamous cell carcinoma, large cell carcinoma and neuroendocrine carcinoma were analysed for EML4-ALK mutations from 4 hospitals in Austria with high expertise in the management of lung cancer. Mutation detection was performed with a two-step procedure. First an immunhistochemical staining was done (ALK confirm/Ventana) and further on positive cases were tested by ALK FISH (dual colour breakapart FISH/Abbott Vysis). Results: In total 639 patients were analysed. EML4-ALK positive immunohistochemical staining was found in 35 patients (5,48%). 14 of these patients (2,19%) showed positive ALK FISH analysis. Conclusions: Frequency of EML-ALK mutations in Austrian patients with NSCLC was similar to other Caucasian peers.

Download Full-text

Lobectomy with Bronchoplastic Procedures for Lung Cancer

Tumori Journal ◽

10.1177/030089167906500513 ◽

1979 ◽

Vol 65 (5) ◽

pp. 643-648 ◽

Cited By ~ 1

Author(s):

Maurizio Valente ◽

Cesare Grandi ◽

Ignazio Cataldo ◽

Giorgio Pizzocaro ◽

Gianni Ravasi

Keyword(s):

Lung Cancer ◽

Cell Carcinoma ◽

Squamous Carcinoma ◽

Large Cell Carcinoma ◽

Distant Metastases ◽

Large Cell ◽

Sleeve Lobectomy ◽

Surgical Specimen ◽

Bronchoplastic Procedures ◽

Oat Cell Carcinoma

From April 1970 to October 1977, 19 patients with lung cancer of the upper lobar bronchus orifice underwent radical lobectomy with major bronchus resection. Sleeve lobectomy was accomplished in 11 cases and wedge lobectomy in the remaining 8. The length of the free bronchial margin in the surgical specimen was less than 1 cm in 3 cases, but limited pulmonary reserve did not allow pneumonectomy. Squamous carcinoma was diagnosed in 14 patients, adenocarcinoma in 2, oat-cell carcinoma in 2, and large cell carcinoma in one. Most cases (70%) were pathological stage I. There was one operative death due to anastomotic leakage (5%), and another patient required pneumonectomy completion. Of 13 patients with non oat-cell carcinoma and adequate bronchial resection, none had local recurrence: 3 patients developed distant metastases, and 10 are alive and disease-free after a follow-up period ranging from 16 to 104 months. The authors conclude that in selected lung cancer patients lobectomy with bronchoplastic procedures is superior to pneumonectomy for tissue sparing advantages.

Download Full-text

Combination chemotherapy with bleomycin, etoposide, and cisplatin in metastatic non-small-cell lung cancer.

Journal of Clinical Oncology ◽

10.1200/jco.1985.3.11.1478 ◽

1985 ◽

Vol 3 (11) ◽

pp. 1478-1485 ◽

Cited By ~ 29

Author(s):

D Osoba ◽

J J Rusthoven ◽

K A Turnbull ◽

W K Evans ◽

F A Shepherd

Keyword(s):

Lung Cancer ◽

Cell Carcinoma ◽

Squamous Cell ◽

Cell Lung Cancer ◽

Performance Status ◽

Large Cell Carcinoma ◽

Large Cell ◽

Small Cell ◽

Entire Group ◽

Small Cell Lung

Fifty-three patients with recurrent and advanced stage (III and IV) non-small-cell lung cancer (NSCLC) were treated with a combination of bleomycin, etoposide (VP-16-213), and cis-diamminedichloroplatinum (BEP). Forty-eight patients were appraisable for response. The response rates were 44% for the entire group, 57% in 30 patients with combined squamous-cell and large-cell carcinoma, and 22% in 18 patients with adenocarcinoma (40%, 50%, and 19%, respectively, if patients not appraisable for response are included as nonresponders). The median survival time of patients with squamous-cell and large-cell carcinoma was slightly longer than that of patients with adenocarcinoma (23 weeks v 19 weeks). Patients with responsive disease survived significantly longer (median, 34 weeks) than did patients with unresponsive disease (median, 16 weeks) (P = .001). In the entire group, the median survival time of patients with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 was better (23 weeks) than of those with a status of 2 or 3 (15 weeks), but this difference was not seen in the subgroup with squamous-cell and large-cell carcinoma (24 weeks v 23 weeks, respectively). Thus, the performance status was not of prognostic value in the histologic subgroups experiencing the best response rate. There were two treatment-related deaths, but otherwise the toxicity of BEP was acceptable. Only four of the 119 treatment cycles were followed by fever even though there was significant neutropenia (0.5 X 10(9)/L) after 20 of 97 treatment cycles. The majority of patients receiving BEP experienced relief of cough, hemoptysis, pain, and fatigue associated with their disease. There was a good correlation between objective responses and palliation of symptoms. Thus, BEP offers good palliation, particularly for patients with squamous-cell and large-cell lung cancer.

Download Full-text

Lung Cancer - Part I

10.2310/im.1184 ◽

2019 ◽

Author(s):

Jeffrey Crawford ◽

John Strickler

Keyword(s):

Lung Cancer ◽

Squamous Cell Carcinoma ◽

Small Cell Lung Cancer ◽

Cell Carcinoma ◽

Squamous Cell ◽

Cell Lung Cancer ◽

Large Cell Carcinoma ◽

Large Cell ◽

Small Cell ◽

Small Cell Lung

In the United States, lung cancer is the second most common cancer, surpassed only by prostate cancer in men and breast cancer in women. But lung cancer is the leading cause of cancer deaths, accounting for 29% and 26% of all cancer-related deaths in men and women, respectively. The four major pathologic cell types of lung cancer are small cell carcinoma, adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Because they have overlapping clinical behaviors and responses to treatment, adenocarcinoma, squamous cell carcinoma, and large cell carcinoma are generally grouped together in the category of non–small cell lung cancer (NSCLC). This review discusses both NSCLC and small cell lung cancer (SCLC), including lung cancer in those who have never smoked, prevention of lung cancer, with sections on diagnosis, biomarkers, treatment, and supportive care. This review contains 7 figures, 10 tables, and 74 references. Keywords: lung cancer, mediastinoscopy, chemoradiotherapy, TNM staging system, pulmonary parenchyma, segmentectomy

Download Full-text

Lung Cancer - Part I

10.2310/fm.1184 ◽

2019 ◽

Author(s):

Jeffrey Crawford ◽

John Strickler

Keyword(s):

Lung Cancer ◽

Squamous Cell Carcinoma ◽

Small Cell Lung Cancer ◽

Cell Carcinoma ◽

Squamous Cell ◽

Cell Lung Cancer ◽

Large Cell Carcinoma ◽

Large Cell ◽

Small Cell ◽

Small Cell Lung

Download Full-text

Lung Cancer Part II

10.2310/im.1672 ◽

2019 ◽

Author(s):

Jeffrey Crawford

Keyword(s):

Lung Cancer ◽

Squamous Cell Carcinoma ◽

Small Cell Lung Cancer ◽

Cell Carcinoma ◽

Squamous Cell ◽

Cell Lung Cancer ◽

Large Cell Carcinoma ◽

Large Cell ◽

Small Cell ◽

Small Cell Lung

In the United States, lung cancer is the second most common cancer, surpassed only by prostate cancer in men and breast cancer in women. But lung cancer is the leading cause of cancer deaths, accounting for 29% and 26% of all cancer-related deaths in men and women, respectively. The four major pathologic cell types of lung cancer are small cell carcinoma, adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Because they have overlapping clinical behaviors and responses to treatment, adenocarcinoma, squamous cell carcinoma, and large cell carcinoma are generally grouped together in the category of non–small cell lung cancer (NSCLC). This review discusses treatment of both NSCLC and small cell lung cancer (SCLC). This review 2 figures, 19 tables, and 90 references. Keywords: lung cancer, mediastinoscopy, chemoradiotherapy, TNM staging system, pulmonary parenchyma, segmentectomy

Download Full-text

Clinical Characteristics and Surgery of Primary Lung Cancer in Younger Patients

Asian Cardiovascular and Thoracic Annals ◽

10.1177/021849230801600509 ◽

2008 ◽

Vol 16 (5) ◽

pp. 387-391 ◽

Cited By ~ 1

Author(s):

Yasunobu Funakoshi ◽

Shin-Ichi Takeda ◽

Yoshihisa Kadota ◽

Takashi Kusu ◽

Hajime Maeda

Keyword(s):

Lung Cancer ◽

Cell Carcinoma ◽

Older Patients ◽

Clinical Characteristics ◽

Early Stage ◽

Survival Rates ◽

Primary Lung Cancer ◽

Large Cell Carcinoma ◽

Large Cell ◽

Younger Patients

Controversy exists regarding the clinical characteristics, pathological findings, and prognosis of patients < 50 years of age with primary lung cancer. The medical records of 4,556 patients diagnosed with primary lung cancer between 1980 and 2004 were reviewed; of these, 305 were < 50 years old. Of 1,335 patients who were surgically treated, 122 were < 50 years old. Females were over-represented in the younger group. Younger patients had a significantly higher incidence of adenocarcinoma and large cell carcinoma, and a lower incidence of squamous cell carcinoma. The resectable rate in younger patients was significantly higher. Overall and among surgically treated patients, the survival rates of younger patients with stage 0-I disease were significantly better than those of older patients. Younger patients with early-stage primary lung cancer had a significantly better prognosis than older patients, although survival in the advanced stages was not significantly different.

Download Full-text

Introduction to Neoplasms of the Lung and Tracheobronchial Tree

Chest Imaging ◽

10.1093/med/9780199858064.003.0044 ◽

2019 ◽

pp. 253-255

Author(s):

Melissa L. Rosado-de-Christenson

Keyword(s):

Lung Cancer ◽

Cell Carcinoma ◽

Lung Neoplasm ◽

Pulmonary Nodules ◽

Large Cell Carcinoma ◽

Large Cell ◽

Cell Types ◽

Tracheobronchial Tree ◽

Pulmonary Neoplasms ◽

Lung Malignancy

The introduction to neoplasms of the lung and tracheobronchial tree addresses the different types of malignant and benign neoplasms of the lung. The most common primary lung neoplasm is lung cancer. It represents the most common cause of cancer mortality in American men and women. Lung cancer is comprised by four major cell types including adenocarcinoma, squamous cell carcinoma, small cell carcinoma and large cell carcinoma. Many patients with lung cancer are symptomatic at presentation and most present with advanced disease. Lung cancer has a variety of imaging manifestations including nodules, masses, post-obstructive atelectasis/pneumonia, intrathoracic lymphadenopathy, extrapulmonary involvement and/or metastatic disease. Carcinoid tumor is an uncommon primary lung malignancy that often affects the airways, but typically exhibits an indolent behavior. Benign pulmonary neoplasms are rare and include neoplasms of the lung and airways such as hamartoma and endobronchial mesenchymal neoplasms. Pulmonary metastases are probably the most common pulmonary neoplasms and usually manifest as multifocal pulmonary nodules and masses.

Download Full-text

Large Cell Carcinoma Mimicking Non Resolving Pneumonia

Journal of Medicine ◽

10.3329/jom.v12i2.8423 ◽

1970 ◽

Vol 12 (2) ◽

pp. 166-169

Author(s):

Mohammad Ashik Imran Khan ◽

MD Titu Miah ◽

MD Shahriar Mahbub ◽

Ratan Das Gupta ◽

HAM Nazmul Ahasan ◽

...

Keyword(s):

Lung Cancer ◽

Chest Pain ◽

Cell Carcinoma ◽

Large Cell Carcinoma ◽

Large Cell ◽

Community Acquired Pneumonia ◽

Young Lady ◽

Common Phenomenon ◽

Diagnostic Challenge

Fever, chest pain, cough in a young lady usually does not ring any alarm bell. We present here a case of a young lady who had typical symptoms of community acquired pneumonia who initially responded to regular antibiotics but later was investigated to have large cell carcinoma. Presentation of lung cancer as non-resolving pneumonia is not a very common phenomenon and diagnosis can present a diagnostic challenge to the clinician. Keyword: Non-resolving pneumonia, Young lady, Chest pain, fever, Large cell Carcinoma, Bangladesh. DOI: http://dx.doi.org/10.3329/jom.v12i2.8423 JOM 2011; 12(2): 166-169

Download Full-text

Is carrot consumption associated with a decreased risk of lung cancer? A meta-analysis of observational studies

British Journal Of Nutrition ◽

10.1017/s0007114519001107 ◽

2019 ◽

Vol 122 (5) ◽

pp. 488-498 ◽

Cited By ~ 2

Author(s):

Hongbin Xu ◽

Heng Jiang ◽

Wei Yang ◽

Fujian Song ◽

Shijiao Yan ◽

...

Keyword(s):

Lung Cancer ◽

Cell Carcinoma ◽

Prospective Cohort ◽

Observational Studies ◽

Meta Analysis ◽

Large Cell Carcinoma ◽

Large Cell ◽

Case Control ◽

Case Control Studies ◽

Epidemiological Evidence

AbstractFindings of epidemiological studies regarding the association between carrot consumption and lung cancer risk remain inconsistent. The present study aimed to summarise the current epidemiological evidence concerning carrot intake and lung cancer risk with a meta-analysis. We conducted a meta-analysis of case–control and prospective cohort studies, and searched PubMed and Embase databases from their inception to April 2018 without restriction by language. We also reviewed reference lists from included articles. Prospective cohort or case–control studies reporting OR or relative risk with the corresponding 95 % CI of the risk lung cancer for the highest compared with the lowest category of carrot intake. A total of eighteen eligible studies (seventeen case–control studies and one prospective cohort study) were included, involving 202 969 individuals and 5517 patients with lung cancer. The pooled OR of eighteen studies for lung cancer was 0·58 (95 % CI 0·45, 0·74) by comparing the highest category with the lowest category of carrot consumption. Based on subgroup analyses for the types of lung cancer, we pooled that squamous cell carcinoma (OR 0·52, 95 % CI 0·19, 1·45), small-cell carcinoma (OR 0·43, 95 % CI 0·12, 1·59), adenocarcinoma (OR 0·34, 95 % CI 0·15, 0·79), large-cell carcinoma (OR 0·40, 95 % CI 0·10, 1·57), squamous and small-cell carcinoma (OR 0·85, 95 % CI 0·45, 1·62), adenocarcinoma and large-cell carcinoma (OR 0·20, 95 % CI 0·02, 1·70) and mixed types (OR 0·61, 95 % CI 0·46, 0·81). Exclusion of any single study did not materially alter the pooled OR. Integrated epidemiological evidence from observational studies supported the hypothesis that carrot consumption may decrease the risk of lung cancer, especially for adenocarcinoma.

Download Full-text

Impact of Histopathological Diagnosis with Ancillary Immunohistochemical Studies on Lung Cancer Subtypes Incidence and Survival: A Population-Based Study

Journal of Cancer Epidemiology ◽

10.1155/2011/275758 ◽

2011 ◽

Vol 2011 ◽

pp. 1-7 ◽

Cited By ~ 3

Author(s):

Andrea Bordoni ◽

Massimo Bongiovanni ◽

Luca Mazzucchelli ◽

Alessandra Spitale

Keyword(s):

Lung Cancer ◽

Cell Carcinoma ◽

Large Cell Carcinoma ◽

Large Cell ◽

Incidence Rates ◽

Small Cell ◽

Histopathological Diagnosis ◽

Cancer Subtypes ◽

Immunohistochemical Studies ◽

The Impact

Purpose. The aim of this study was to assess the impact of immunohistochemical- (IHC-) studies on incidence and survival of lung cancer histotypes.Patients and Methods. Lung cancers occurred in southern Switzerland between 1996 and 2010 were selected by the Ticino Cancer Registry and categorised into adenocarcinoma (AC), squamous-cell-carcinoma (SqCC), small-cell-carcinoma (SmCC), and large-cell carcinoma/non-small-cell lung cancer (LCC/NSCLC). Incidence rates, annual-percentage-change (APC), and two-year overall survival (OS) (follow-up: 31.12.2010) were performed.Results. 2467 cases were selected: 997 (40.4%) AC; 522 (21.2%) LCC/NSCLC, 378 (15.3%) SmCC, and 570 (23.1%) SqCC. Trend-analysis showed significant increase in AC (APC: 4.6; 95% CI: 3.1; 6.0) and decrease of LCC/NSCLC, with significant joinpoint in 2003 (APC: −14.7; 95% CI: −21.6; −7.1). Improved OS and decreased OS were detected in SqCC and LCC/NSCLC, respectively.Conclusions. This study highlights that diagnosis with ancillary immunohistochemical studies will change incidence and survival of precisely defined lung cancer subtypes. It calls attention to the need for cautious interpretation of studies and clinical trials, where the diagnosis was based on histology unaccompanied by IHC studies, and to the need of standardised diagnostic procedures.

Download Full-text